brazikumab   

GtoPdb Ligand ID: 9293

Synonyms: AMG 139 | AMG-139 | MEDI2070
Compound class: Antibody
Comment: Brazikumab (AMG 139, MEDI2070) is a fully human anti-IL23A monoclonal antibody in clinical development for autoimmune indications.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent WO2011056600 [3].
Bioactivity Comments
It is unclear which anti-IL-23 antibody in patent WO2011056600 is AMG 139, although antibodies B and E were crystalised to produce X-ray structures, suggesting these were preferred agents [3]. In binding affinity experiments using recombinant human IL-23, all of the chosen antibodies produced equilibrium dissociation constant (KD) values <4pM [3].
Selectivity at ligand targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
IL-23A Hs Antibody Binding >11.4 pKd - 3
pKd >11.4 (Kd <4x10-12 M) [3]
Description: Measured using KinExA technology (a kinetic exclusion assay)